AlphaCrest Capital Management’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-20,234
| Closed | -$621K | – | 324 |
|
|
2022
Q3 | $621K | Buy |
20,234
+6,934
| +52% | +$213K | 0.04% | 879 |
|
|
2022
Q2 | $391K | Sell |
13,300
-13,900
| -51% | -$409K | 0.02% | 1031 |
|
|
2022
Q1 | $875K | Buy |
27,200
+17,389
| +177% | +$559K | 0.05% | 616 |
|
|
2021
Q4 | $438K | Buy |
9,811
+3,411
| +53% | +$152K | 0.02% | 1147 |
|
|
2021
Q3 | $323K | Buy |
+6,400
| New | +$323K | 0.02% | 1077 |
|
|
2021
Q2 | – | Sell |
-13,400
| Closed | -$765K | – | 1244 |
|
|
2021
Q1 | $765K | Buy |
+13,400
| New | +$765K | 0.04% | 615 |
|
|
2020
Q3 | – | Sell |
-16,900
| Closed | -$409K | – | 1113 |
|
|
2020
Q2 | $409K | Buy |
+16,900
| New | +$409K | 0.07% | 471 |
|
|
2019
Q4 | – | Sell |
-14,100
| Closed | -$216K | – | 1268 |
|
|
2019
Q3 | $216K | Buy |
+14,100
| New | +$216K | 0.01% | 1196 |
|